Viewing nowSamsita 50 mg (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.

MFDS item code 202004040 · Approved 2020.05.29 · Insurance code 642308480
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone to patients who have not previously received diabetes medication. However, if achieving blood sugar control is difficult with monotherapy, it may be combined with metformin. Additionally, it can be used together with any of the following medications when adequate blood sugar control cannot be achieved with monotherapy: sulfonylureas, metformin, thiazolidinediones, or insulin. This medication may also be used in cases where blood sugar control cannot be effectively managed with multiple drug regimens.
This medicine is administered at 100 mg once daily as monotherapy or in combination therapy, with a maximum daily dose of 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dose adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. The dose for patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2) is 50 mg once daily. 4. The dose for patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2) is 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.
This medication can very rarely cause serious allergic reactions; therefore, if symptoms such as rash, difficulty breathing, or swelling of the face or neck occur after taking the medication, discontinue use immediately and consult a doctor. It may also cause a serious inflammation of the pancreas called pancreatitis; thus, if abdominal pain, nausea, vomiting, or sudden weight loss occurs during use, inform medical personnel immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in those with allergies to the drug or its components. Patients with impaired kidney function may experience delayed excretion of this medication, necessitating dose adjustments or careful use as directed by a physician. During treatment with this medication, side effects such as cold-like symptoms, headache, indigestion, diarrhea, and nausea may occur, and hypoglycemic symptoms might also be experienced; hence, it is important to regularly monitor blood sugar levels. Particularly, when taken with insulin or sulfonylureas, the risk of hypoglycemia may be increased, warranting dosage adjustments of these medications. This medication can cause severe joint pain or skin blistering conditions; thus, any such symptoms should be reported to a physician immediately. Pregnant or nursing women are advised against taking this medication, and its safety and efficacy have not been established in children or adolescents under 18 years of age. Elderly patients should be evaluated for renal function before starting this medication and regularly assessed thereafter due to potential renal impairment. In case of overdose, standard emergency treatment should be initiated, and hemodialysis may be employed to remove the medication if necessary. This medication has minimal interactions with other diabetes treatments or certain medications but caution is required when taking specific drugs; consultation with a doctor or pharmacist is recommended.
Hypersensitivity, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative skin disease, acute pancreatitis, hypoglycemia, upper respiratory infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, constipation, vomiting, severe arthralgia accompanied by disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, indigestion, dizziness, increased serum triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air ingress, and keep it at room temperature between 1 to 30 degrees Celsius. This will help maintain the medication's effectiveness.
Pale yellow pink round biconvex film-coated tablet
30 tablets - 10 tablets/PTP [x3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.